Hoth Therapeutics: API and product agreement with WuXi STA
Pharma company Hoth Therapeutics has entered into contracts with WuXi STA covering development and manufacturing of the active pharmaceutical ingredient (API) and formulation of drug product for HT-KIT. HT-KIT is a new molecular entity (NME) morpholino oligonucleotide therapy in development for targeting mast cell-derived cancers (aggressive systemic mastocytosis, or ASM; systemic mastocytosis with associated hematological neoplasm (SM-AHN); or mast cell leukemia, MCL and anaphylaxis.
"Initiation of API and drug formulation development is a huge leap towards getting HT-KIT into clinical trials, which is a large focus for Hoth Therapeutics in the next year,” said Stefanie Johns, Hoth Therapeutics chief scientific officer. "We are confident in WuXi STA’s experience in manufacturing morpholino oligonucleotides for clinical and commercial applications to help expedite our program for HT-KIT."